Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Larsen

Nurse Practitioner, Adult Health Greenville, NC Nurse Practitioner

NPI 1487021358 CMS profile 10472732

2210 Hemby Ln, Greenville, NC 27834

Open in the dashboard

General payments

$9,111

524 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Larsen of Greenville, NC is reported in the CMS Open Payments database as having received $9,111 across 524 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,150 106
2024 General $2,013 111
2023 General $1,750 101
2022 General $1,768 112
2021 General $1,430 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Larsen
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Heather Larsen were reported at $2,150. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Heather Larsen Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,430 $138 $43–$438 $132
2022 $1,768 $165 $54–$494 $149
2023 $1,750 $178 $61–$549 $160
2024 $2,013 $186 $62–$575 $164
2025 $2,150 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,810 172 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $856 48 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $739 43 payments
  4. Janssen Biotech, Inc. $667 38 payments
  5. Ironwood Pharmaceuticals, Inc $512 41 payments
  6. Phathom Pharmaceuticals, Inc. $309 14 payments
  7. Genzyme Corporation $297 11 payments
  8. Aimmune Therapeutics, Inc. $295 13 payments
  9. RedHill Biopharma Inc. $283 15 payments
  10. Pfizer Inc. $280 23 payments
  11. Other $2,063 106 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,095 523 payments
  2. Education $16 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $1,503 79 payments
  2. ENTYVIO $619 35 payments
  3. SKYRIZI Immunology $598 28 payments
  4. ZENPEP $525 25 payments
  5. STELARA $520 30 payments
  6. Linzess Gi $512 41 payments
  7. XIFAXAN $478 24 payments
  8. LINZESS Gastroenterology $436 43 payments
  9. TRULANCE $427 26 payments
  10. SKYRIZI Immunology $413 21 payments
  11. Other $5,378 311 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,718

Median for Nurse Practitioner: 389

Drug cost

$1,198,078

Median for Nurse Practitioner: $21,885

Branded share of claims

17.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 19 $523,782
Humira(Cf) Pen Adalimumab Brand 25 $198,832
Linzess Linaclotide Brand 198 $180,134
Creon Lipase/Protease/Amylase Brand 41 $163,235
Trulance Plecanatide Brand 42 $34,164
Xifaxan Rifaximin Brand 12 $26,120
Mesalamine Generic 53 $14,452
Pantoprazole Sodium Generic 777 $9,273
Famotidine Generic 570 $8,471
Dexlansoprazole Dr Dexlansoprazole Brand 21 $7,486

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$55,486

Medicare's payments for the services billed

Medicare patients

563

Average age 74

Services billed

919

366 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 36%
Ischemic heart disease 34%
Chronic kidney disease 30%
Depression 25%
COPD 20%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $274
$274 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $250
$250 — —
DUPIXENT
  • GENZYME CORPORATION $112
  • Regeneron Healthcare Solutions, Inc. $109
$222 — —
SKYRIZI
  • AbbVie, Inc. $180
$180 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $100
  • AbbVie, Inc. $64
$163 198 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

524 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record